natgillin/translations-raw huggingface dataset:
plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding.
skupaj z acetilsalicilno kislino, če ne morete prejemati "peroralnih antikoagulantov", ali če nimate tveganja za večjo krvavitev.
There have been a number of retrospective analyses, however, to evaluate this effect in patients treated with clopidogrel for whom there are genotyping results: CURE (n=2721), CHARISMA (n=2428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1477), and ACTIVE-A (n=601), as well as a number of published cohort studies.
Opravljene pa so bile številne retrospektivne analize za oceno tega učinka pri bolnikih, zdravljenih s klopidogrelom, za katere so na voljo rezultati genotipizacije: CURE (n = 2721), CHARISMA (n = 2428), CLARITY-TIMI 28 (n = 227), TRITON-TIMI 38 (n = 1477) in ACTIVE-A (n = 601), poleg tega pa tudi številne objavljene kohortne študije.
At Day 14, platelet function testing (PFT) was performed.
Štirinajsti dan so opravili preskušanje funkcije trombocitov (PFT - platelet function testing).
This randomized, open-label trial included 2,610 biomarker-positive ACS patients after successful PCI.
To randomizirano, odprto preskušanje je vključilo 2.610 bolnikov z AKS in pozitivnimi biološkimi označevalci po uspešni PKI.
Pregnancy and breast-feeding It is preferable not to take this medicine during pregnancy.
Nosečnost in dojenje Priporočljivo je, da tega zdravila ne jemljejo nosečnice.
per day to be taken orally with or without food, and at the same time each day.
na dan, ki jo lahko vzamete s hrano ali brez nje; odmerek morate jemati vsak dan ob istem času.
Kounis syndrome (vasospastic allergic angina / allergic myocardial infarction) in the context of a hypersensitivity reaction due to clopidogrel*
Kounisov sindrom (vazospastična alergijska angina / alergijski miokardni infarkt) v okviru preobčutljivostne reakcije zaradi klopidogrela*
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%.
V CAPRIE je bila pri bolnikih, zdravljenih bodisi s klopidogrelom ali ASA, celokupna incidenca kakršnihkoli krvavitev 9,3 %.
De-escalation of P2Y12 Inhibitor Agents in ACS
Deeskalacija zaviralcev P2Y12 pri AKS
is unlikely to affect your ability to drive or to use machines.
vplivalo na vašo sposobnost za vožnjo ali upravljanje strojev.
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups.
V študiji COMMIT je bil skupni delež večjih necerebralnih krvavitev ali cerebralne krvavitve nizek in podoben v obeh skupinah.
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or lansoprazole.
Manj izrazita zmanjšana izpostavljenost presnovkov je bila opažena pri pantoprazolu ali lansoprazolu.
Apart from the specific medicinal product interaction information described above, interaction studies with clopidogrel and some medicinal products commonly administered in patients with atherothrombotic disease have not been performed.
Razen zgoraj navedenih podatkov o specifičnih interakcijah z zdravili, študij o interakcijah klopidogrela z nekaterimi drugimi zdravili, ki jih bolniki z aterotrombotično boleznijo pogosto uporabljajo, niso izvedli.
Patients with a confirmed diagnosis of acquired haemophilia should be managed and treated by specialists, and clopidogrel should be discontinued.
Bolnike s potrjeno diagnozo pridobljene hemofilije morajo obravnavati in zdraviti zdravniki specialisti, zdravljenje s klopidogrelom pa je treba prekiniti.
Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.
Absorpcija je najmanj 50-odstotna, in to zaradi presnovkov klopidrogela, ki se izločajo z urinom.
You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Clopidogrel Krka d.d.
Povedati so vam morali, da so "peroralni antikoagulanti" pri tej motnji učinkovitejši kot acetilsalicilna kislina ali kombinirana uporaba zdravila Clopidogrel Krka d.d.
The binding is non-saturable in vitro over a wide concentration range.
Pri vezavi in vitro ne pride do nasičenosti v širokem koncentracijskem razponu.
looks like and contents of the pack The film-coated tablets are pink, round and slightly convex.
in vsebina pakiranja Filmsko obložente tablete so rožnate, okrogle in rahlo izbočene.
After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed.
Po enkratnem in večkratnih peroralnih odmerkih po 75 mg na dan se klopidogrel hitro absorbira.
in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever.
v kombinaciji z acetilsalicilno kislino, učinkovino, ki je prisotna v številnih zdravilih, ki se uporabljajo za lajšanje bolečine in zniževanje zvišane telesne temperature.
The efficacy of clopidogrel was observed independently of the dose of ASA (75-325 mg once daily).
Učinkovitost klopidogrela je bila neodvisna od odmerka ASA (75-325 mg enkrat na dan).
The primary endpoint (the combined incidence of CV death, MI, stroke and BARC bleeding grade ≥2 at 12 months) was met showing non-inferiority.
Primarni opazovani dogodek (kombinirana pojavnost SŽ smrti, MI, možganske kapi in krvavitev ≥ 2 po BARC po 12 mesecih) je bil dosežen in to dokazuje neinferiornost.
The de-escalated patients underwent high platelet reactivity (HPR) testing.
Bolniki z deeskaliranjem so opravili preskušanje visoke reaktivnosti trombocitov (HPR - high platelet reactivity).
Detailed information is available on the European Medicines Agency website: http://www.ema.europa.eu
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery .
V CURE število velikih krvavitev s klopidogrelom in ASA ni bilo prekoračeno v 7 dneh po koronarni premostitveni operaciji pri bolnikih, ki so prenehali z zdravljenjem več kot 5 dni pred kirurškim posegom.
The patient population included 19.7% women and 29.2% patients ≥ 65 years.
Populacijo bolnikov je sestavljalo 19,7 % žensk in 29,2 % bolnikov, starih 65 let ali več.
Exposure of clopidogrel and average platelet inhibition can be decreased with concomitant use of ritonavir.
Izpostavljenost klopidogrelu in povprečno zaviranje trombocitov se lahko ob sočasni uporabi ritonavirja zmanjšata.
Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal.
Bolniki so morali imeti bodisi spremembe elektrokardiograma (EKG), združljive z novo ishemijo, ali povišane vrednosti srčnih encimov ali troponina I ali T na nad dvakratno zgornjo mejo normalnega.
Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human plasma proteins (98% and 94% respectively).
Klopidogrel in glavni krožeči (neaktivni) presnovek se in vitro reverzibilno vežeta na humane plazemske beljakovine (98- oz. 94-odstotno).
Seventy-three percent (73%) of patients enrolled into the ACTIVE-A study were unable to take VKA due to physician assessment, inability to comply with INR (international normalised ratio) monitoring, predisposition to falling or head trauma, or specific risk of bleeding; for 26% of the patients, the physician's decision was based on the patient's unwillingness to take VKA.
Triinsedemdeset odstotkov (73 %) bolnikov, vključenih v študijo ACTIVE-A, je bilo neprimernih za prejemanje VKA po zdravnikovi oceni, nezmožnosti upoštevanja kontrol INR (internacionalnega normaliziranega razmerja), nagnjenosti k padcem ali poškodbe glave, ali specifičnega tveganja krvavitev; pri 26 % bolnikov je zdravnikova odločitev temeljila na tem, da bolnik ni želel jemati VKA.
The safety and efficacy of clopidogrel have been evaluated in 5 double-blind studies involving over 88,000 patients: the CAPRIE study, a comparison of clopidogrel to ASA, and the CURE, CLARITY, COMMIT and ACTIVE-A studies comparing clopidogrel to placebo, both medicinal products given in combination with ASA and other standard therapy.
Varnost in učinkovitost klopidogrela so vrednotili v 5 dvojno slepih študijah, v katere je bilo vključenih več kot 88.000 bolnikov: študija CAPRIE je obsegala primerjavo klopidogrela in ASA, v študijah CURE, CLARITY, COMMIT in ACTIVE-A pa so primerjali klopidogrel s placebom; oboje pa so bolniki dobivali v kombinaciji z ASA in drugo standardno terapijo.
In CURE, CLARITY, ACTIVE-A and one of the cohort studies (Trenk), no increased event rate was observed based on metaboliser status.
V študijah CURE, CLARITY, ACTIVE-A in eni od kohortnih študij (Trenk) niso odkrili večjega deleža dogodkov glede na metabolizatorsko stanje.
Side effects with frequency not known (frequency cannot be estimated from the available data): Hypersensitivity reactions with chest or abdominal pain, persistent low blood sugar symptoms.
Neželeni učinki z neznano pogostnostjo (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti): Preobčutljivostne reakcije z bolečinami v prsih ali trebuhu, vztrajajoči znaki nizke vrednosti sladkorja v krvi.
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy.
V študiji CURE je 823 (6,6 %) bolnikov sočasno jemalo antagoniste receptorja glikoproteina IIb/IIIa.
Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by CYP2C9 can be safely co-administered with clopidogrel.
Podatki študije CAPRIE kažejo, da se lahko fenitoin in tolbutamid, ki se presnavljata s CYP2C9, sočasno s klopidogrelom varno uporabljata.
Warnings and precautions If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel Krka d.d.
Opozorila in previdnostni ukrepi Če katerokoli od spodaj navedenih stanj velja za vas, morate o tem obvestiti svojega zdravnika, preden boste vzeli zdravilo Clopidogrel Krka d.d.
Although the clinical relevance of these findings is uncertain, there have been spontaneous reports of HIV-infected patients treated with boosted ART, who have experienced reocclusive events after de-obstruction or have suffered thrombotic events under a clopidogrel loading treatment schedule.
Čeprav je klinični pomen teh opažanj negotov, obstajajo sponatna poročila o bolnikih, okuženih z virusom HIV, zdravljenih z okrepljenim protiretrovirusnim zdravljenjem, ki so doživeli ponovne okluzivne dogodke po odpravi obstrukcije ali so doživeli trombotične dogodke med zdravljenjem s polnilnim odmerkom klopidogrela.
The population included 27.8% women, 58.4% patients ≥ 60 years (26% ≥ 70 years) and 54.5% patients who received fibrinolytics.
Populacijo bolnikov je sestavljalo 27,8 % žensk, 58,4 % bolnikov, starih 60 let ali več (26 % ≥ 70 let), in 54,5 % bolnikov, ki so dobivali fibrinolitike.
Bleeding time prolonged, neutrophil count decreased, platelet count decreased * Information related to clopidogrel with frequency “not known”.
Preiskave podaljšan čas krvavitve, zmanjšano število nevtrofilcev, zmanjšano število trombocitov * Podatki se nanašajo na klopidogrel s pogostnostjo “neznani”.
The ACTIVE-A study (N=7,554) was a multicenter, randomized, double-blind, placebo-controlled study which compared clopidogrel 75 mg/day + ASA (N=3,772) to placebo + ASA (N=3,782).
Študija ACTIVE-A (n = 7.554) je bila multicentrična, randomizirana, dvojno slepa, s placebom kontrolirana študija, ki je primerjala klopidogrel 75 mg/dan + ASA (n = 3.772) in placebo + ASA (n = 3.782).
Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excl. heparin, ATC code: B01AC-04.
Farmakoterapevtska skupina: antitrombotiki, zaviralci agregacije trombocitov brez heparina, oznaka ATC: B01AC04.
Based on enrollment criteria, physicians enrolled patients in ACTIVE-W if they were candidates for vitamin K antagonist (VKA) therapy (such as warfarin).
Na podlagi meril za vključitev so zdravniki bolnike vključili v ACTIVE-W, če so bili kandidati za zdravljenje z antagonistom vitamina K (VKA), npr. z varfarinom.
Overall, 645 of 646 patients with STEMI or NSTEMI or unstable angina were analyzed (de-escalated DAPT (n=322); unchanged DAPT (n=323)).
V celoti so analizirali 645 od 646 bolnikov s STEMI, NSTEMI ali nestabilno angino pektoris (deeskalirano DAPT (n = 322), nespremenjeno DAPT (n = 323)).
• Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
- odraslih bolnikih z miokardnim infarktom (od nekaj dni do manj kot 35 dni), ishemično kapjo (od 7 dni do manj kot 6 mesecev) ali dokazano periferno arterijsko boleznijo.
The ACTIVE-W study demonstrated that anticoagulant treatment with vitamin K antagonists was more effective than with clopidogrel and ASA.
Študija ACTIVE-W je pokazala, da je bilo zdravljenje z antagonisti vitamina K učinkovitejše kot zdravljenje s klopidogrelom in ASA.
TOPIC (Timing Of Platelet Inhibition after acute Coronary syndrome) This randomized, open-label trial included ACS patients requiring PCI.
Študija TOPIC (Tempiranje zavrtja trombocitov po akutnem koronarnem sindromu) To randomizirano, odprto preskušanje je vključilo bolnike z AKS, ki so potrebovali PKI.
If HPR≥46 units, the patients were escalated back to prasugrel 5 or 10 mg/d for 11.5 months; if HPR<46 units, the patients continued on clopidogrel 75 mg/d for 11.5 months.
Če je bil rezultat HPR ≥ 46 enot, je bila izvedena ponovna eskalacija na prasugrel 5 mg ali 10 mg/dan za 11,5 meseca; če je bil rezultat HPR < 46 enot, so bolniki nadaljevali zdravljenje s klopidogrelom 75 mg/dan v obdobju 11,5 meseca.
• If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain.
- če imate zdravstveno stanje, ki trenutno povzroča krvavitev, npr. rana na želodcu ali možganska krvavitev.
The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed below.
Klinično pomembni neželeni učinki, zabeleženi v študijah CAPRIE, CURE, CLARITY in COMMIT, so predstavljeni spodaj.
• If you suffer from severe liver disease.
- če imate hudo jetrno obolenje.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including medicines obtained without a prescription.
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo.
Due to the irreversible binding, platelets exposed are affected for the remainder of their lifespan (approximately 7-10 days) and recovery of normal platelet function occurs at a rate consistent with platelet turnover.
Zaradi ireverzibilne vezave se učinek na izpostavljene trombocite ohrani vso njihovo preostalo življenjsko dobo (približno 7-10 dni), normalno delovanje trombocitov pa se obnovi s hitrostjo, ki je v skladu s premeno trombocitov.
• Paediatric population Clopidogrel should not be used in children because of efficacy concerns (see section 5.1).
Klopidogrel naj se pri otrocih ne uporablja iz razlogov, ki zadevajo učinkovitost (glejte poglavje 5.1.
The recommended dose, including for patients with a condition called ‘atrial fibrillation' (an irregular heartbeat), is one 75 mg tablet of Clopidogrel Krka d.d.
Priporočeni odmerek, vključno za bolnike, ki imajo bolezensko stanje, imenovano "atrijska fibrilacija" (nepravilen srčni utrip), je ena 75 mg tableta zdravila Clopidogrel Krka d.d.
In addition to clinical studies experience, adverse reactions have been spontaneously reported.
Poleg neželenih učinkov v kliničnih študijah so bili neželeni učinki prijavljeni tudi spontano.
For patients over 75 years of age clopidogrel should be initiated without a loading dose.
Pri starejših od 75 let začnemo zdravljenje s klopidogrelom brez udarnega odmerka.
The primary endpoint was the occurrence of the composite of an occluded infarct-related artery on the predischarge angiogram, or death or recurrent MI before coronary angiography.
Primarni opazovani dogodek je bila sočasna navzočnost zamašene arterije, ki je povzročila MI na angiogramu pred odpustom ali smrt ali ponovni miokardni infarkt pred koronarno angiografijo.
The major exclusion criteria for patients were documented peptic ulcer disease within the previous 6 months; prior intracerebral hemorrhage; significant thrombocytopenia (platelet count < 50 x 10
Glavna merila za nevključitev bolnikov so bila potrjena peptična ulkusna bolezen v preteklih 6 mesecih, predhodna intracerebralna krvavitev, pomembna trombocitopenija (število trombocitov < 50 x 10
- You have an irregular heartbeat, a condition called ‘atrial fibrillation', and you cannot take medicines known as ‘oral anticoagulants' (vitamin K antagonists) which prevent new clots from forming and prevent existing clots from growing.
- imate neredno bitje srca, motnjo, imenovano "atrijska fibrilacija", in ne morete prejemati zdravil, imenovanih "peroralni antikoagulanti" (antagonisti vitamina K), ki preprečujejo nastajanje novih krvnih strdkov in preprečujejo rast obstoječih krvnih strdkov.
Bleeding and haematological disorders
Krvavitve in hematološke motnje
In contrast, post-hoc analyses demonstrated statistically significant increases in the bleeding risk with the more potent P2Y12 inhibitors, occurring predominantly during the maintenance phase, after the first month post-ACS.
Nasprotno pa so post hoc analize pokazale, da je z močnejšimi zaviralci P2Y12 statistično značilno večje tveganje za krvavitve; krvavitve se pojavijo pretežno med fazo vzdrževalnega zdravljenja, po prvem mesecu po AKS.
In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel plus ASA, and 6.3% for placebo plus ASA.
Pri bolnikih, ki so ostali na zdravljenju do 5 dni pred koronarno premostitveno operacijo, je bil delež dogodkov 9,6 % za klopidogrel in ASA in 6,3 % za placebo in ASA.
A total of 23.0% of patients received anti-arrhythmics, 52.1% beta-blockers, 54.6% ACE inhibitors, and 25.4% statins.
V celoti je 23,0 % bolnikov prejemalo antiaritmike, 52,1 % blokatorje beta, 54,6 % zaviralce ACE in 25,4 % statine.
This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel-treated group and 363 (5.8%) in the placebo-treated group].
Ta korist je v glavnem nastala kot posledica statistično pomembnega zmanjšanja incidence MI (287 /4,6 %/ v skupini, zdravljeni s klopidogrelom, in 363 /5,8 %/ v placebo skupini).
Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing.
C-označenega klopidogrela pri človeku, se ga je približno 50 % izločilo z urinom in približno 46 % z blatom v 120 urnem intervalu po odmerjanju.
Overall, clopidogrel 75 mg/day was comparable to ASA 325 mg/day in CAPRIE regardless of age, gender and race.
V celoti je bil klopidogrel v odmerku 75 mg/dan v študiji CAPRIE, primerljiv z ASA v odmerku 325 mg/dan, ne glede na starost, spol ali raso.
Manufacturer:
Proizvajalec
In view of the lack of data, clopidogrel cannot be recommended during the first 7 days after acute ischaemic stroke.
Nedavna ishemična kap Zaradi pomanjkanja podatkov se klopidogrel ne priporoča prvih sedem dni po akutni ishemični kapi.
Thienopyridines may cause mild to severe allergic reactions such as rash, angioedema, or haematological cross-reactions such as thrombocytopaenia and neutropaenia.
Tienopiridini lahko povzročijo blage do hude alergijske reakcije, na primer izpuščaj, angioedem ali hematološke navzkrižne reakcije, na primer trombocitopenijo in nevtropenijo.
• Hypersensitivity to the active substance or to any of the excipients listed in section 2 or section
- Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 2 ali v poglavju 6.1.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel Krka d.d..
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta, preden vzamete zdravilo Clopidogrel Krka d.d..
Thus, beyond 3 months of treatment, the benefit observed in the clopidogrel + ASA group was not further increased, whereas the risk of haemorrhage persisted (see section 4.4).
Tako se po več kot 3-mesečnem zdravljenju opažena korist v skupini, ki je jemala klopidogrel in ASA, ni povečevala, tveganje za krvavitev pa je ostalo (glejte poglavje 4.4).
contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products.
vsebuje klopidogrel in spada v skupino zdravil, ki se imenujejo zaviralci agregacije trombocitov.
Recent myocardial infarction (MI), recent stroke or established peripheral arterial disease The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction (<35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD).
Nedavni miokardni infarkt (MI), nedavna kap ali ugotovljena periferna arterijska bolezen (PAD) Študija CAPRIE je vključevala 19.185 bolnikov z aterotrombozo, ki se je odrazila z nedavnim miokardnim infarktom (<35 dni), ishemično kapjo (med 7 dni in 6 meseci) ali razvito periferno arterijsko boleznijo (PAD).
Ask your pharmacist how to throw away you no longer use.
O načinu odstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte s farmacevtom.
film-coated tablet
filmsko obložena tableta
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenija TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Nemčija
There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers or antacids interfere with antiplatelet activity of clopidogrel.
Ni dokazov, da druga zdravila za zmanjševanje želodčne kisline, npr. antagonisti histaminskih receptorjev H2 ali antacidi, ovirajo antitrombocitno delovanje klopidogrela.
Some other medicines may influence the use of Clopidogrel Krka d.d.
Nekatera druga zdravila lahko vplivajo na jemanje zdravila Clopidogrel Krka d.d.
This benefit was consistent across all prespecified subgroups including patients' age and gender, infarct location, and type of fibrinolytic or heparin used.
Ta koristni učinek se je pojavljal v vseh prehodno opredeljenih podskupinah glede na bolnikovo starost ali spol, mesto infarkta in vrsto uporabljenega fibrinolitika ali heparina.
You should also be given acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever as well as to prevent blood clotting) by your doctor.
Zdravnik vam bo moral predpisati tudi acetilsalicilno kislino (učinkovina, ki je v številnih zdravilih proti bolečinam in za zniževanje zvišane telesne temperature, kot tudi za preprečevanje strjevanja krvi).
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3, 3-6, 6-9 and 9-12 month study intervals, respectively.
Nove srčno-žilne dogodke (primarni opazovani dogodek) so preprečili z zmanjšanjem RT za 22 % (IZ: 8,6, 33,4), 32 % (IZ: 12,8, 46,4), 4 % (IZ: -26,9, 26,7), 6 % (IZ: -33,5, 34,3) in 14 % (IZ: -31,6, 44,2) med intervali, ki so trajali 0-1, 1-3, 3-6, 6-9 oziroma 9-12 mesecev.
CYP2C8 substrate medicinal products: Clopidogrel has been shown to increase repaglinide exposure in healthy volunteers.
Zdravila, ki so substrati CYP2C8: Klopidogrel pri zdravih prostovoljcih poveča izpostavljenost repaglinidu.
Blister of OPA/Alu/PVC-Alu containing 7, 14, 28, 30, 50, 56, 84, 90 and 100 film-coated tablets in the box.
Na voljo so v pretisnih omotih (OPA/Al/PVC-Al) po 7, 14, 28, 30, 50, 56, 84, 90 in 100 filmsko obloženih tablet v škatli.